Navigation Links
HealthSouth Declares Dividend on 6.5% Series A Convertible Perpetual Preferred Stock
Date:6/12/2009

BIRMINGHAM, Ala., June 12 /PRNewswire-FirstCall/ -- HealthSouth Corporation (NYSE: HLS) announced today that its board of directors has declared a regular quarterly dividend of $16.25 per share on its 6.5% Series A Convertible Perpetual Preferred Stock, payable on July 15, 2009, to holders of record on July 1, 2009.

About HealthSouth

HealthSouth is the nation's largest provider of inpatient rehabilitative healthcare services. Operating in 26 states across the country and in Puerto Rico, HealthSouth serves patients through its network of inpatient rehabilitation hospitals, long-term acute care hospitals, outpatient rehabilitation satellites, and home health agencies. HealthSouth strives to be the nation's preeminent provider of inpatient rehabilitative healthcare services and can be found on the Web at www.healthsouth.com.

    Media Contact:
    Andy Brimmer, 205-410-2777

    Investor Relations Contact:
    Mary Ann Arico, 205-969-6175
    maryann.arico@healthsouth.com


'/>"/>
SOURCE HealthSouth Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. HealthSouth Announces Date of 2009 Second Quarter Earnings Conference Call
2. Court Rules in Favor of HealthSouth in Litigation Involving General Medicine, P.C.
3. HealthSouth to Present at 34th Annual Deutsche Bank Health Care Conference
4. HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009
5. HealthSouth to Present at Bairds 2009 Growth Stock Conference
6. HealthSouth to Hold Annual Stockholder Meeting
7. HealthSouth Announces Date of 2009 First Quarter Earnings Conference Call
8. HealthSouth Declares Dividend on 6.5% Series A Convertible Perpetual Preferred Stock
9. HealthSouth to Present at Barclays Capital Global Healthcare Conference
10. HealthSouth Issues Preliminary Comments on the Presidents Healthcare Budget Proposal and Announces Plans to Host a Conference Call
11. HealthSouth Reports Results for Fourth Quarter Ended December 31, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... ... ... As a leading dental practice, Wall Centre Dental supports Stroke Awareness Month ... bleeding gums in Vancouver, BC, may be developing gingivitis, the first stage of ... and diabetes. Drs. Parviz Roshan, Siamak Tehrani and Milton Reskovich offer laser gum therapy ...
(Date:6/20/2017)... ... June 20, 2017 , ... This year, participants in the ... finding product improvements that could reduce the occurrence of unplanned extubations (UEs). ... breathing or to provide medication. Sometimes, patient movement can cause unplanned extubations which ...
(Date:6/20/2017)... ... June 20, 2017 , ... Uniform Advantage ... featuring seven new products designed to create tailored looks and athleisure-inspired outfits. UA Flex ... cotton easy care stretch twill. , With trendy looks hitting the medical community, UA ...
(Date:6/20/2017)... ... , ... John D'Eri, CEO of Rising Tide Car Wash , will ... during the Autism Society of America 's 49th annual conference to be held ... (DJFF) was founded in 2002 as the nation's first autism organization focused exclusively ...
(Date:6/20/2017)... ... June 20, 2017 , ... International water ... The Sharon Kleyne Hour Power of Water, Global Climate Change and Your Health ... world’s water crisis and how it affects the human eyes. , According ...
Breaking Medicine News(10 mins):
(Date:6/9/2017)... , June 9, 2017 AirXpanders, Inc. ... focused on the design, manufacture, sale and distribution of ... on the progress of its commercial roll-out in ... available in more than one hundred (100) medical institutions ... AeroForm offers a needle-free alternative for women who ...
(Date:6/7/2017)... -- Endo International plc (NASDAQ: ENDP ) ... Joseph R. Goodwin , U.S. District Court Judge for ... , entered a case management order in MDL 2325, ... Litigation (the "MDL") that includes a provision requiring plaintiffs ... on specific causation within one hundred twenty (120) days ...
(Date:6/3/2017)... June 3, 2017  Eli Lilly and Company ... results from the Phase 3 MONARCH 2 study ... 6 inhibitor, in combination with fulvestrant, significantly improved ... alone in women with hormone-receptor-positive (HR+), human epidermal ... who have relapsed or progressed after endocrine therapy ...
Breaking Medicine Technology: